search
Back to results

Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas

Primary Purpose

Head Trauma, Craniocerebral Injuries, Crushing Skull Injury

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
InfraScanner 2000™
Sponsored by
Duke University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Head Trauma

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Any patient who presents to Duke University Hospital with suspected head trauma and receives a brain CT scan will be considered for this study.

Exclusion Criteria:

  • None

Sites / Locations

  • Duke University Medical Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

InfraScanner 2000™

Arm Description

All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ within 30 minutes of CT. Patients will be scanned using the InfraScanner 2000™ within 30 minutes of each subsequent CT. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.

Outcomes

Primary Outcome Measures

Sensitivity of InfraScanner 2000 TM to Detect Any Size Hematoma at the Patient Level
Percentage of subjects with hematomas detected by CT who had hematoma detected by Infrascanner 2000 TM.
Sensitivity of InfraScanner 2000 TM to Detect Any Size Hematoma at the Scan Level
Percentage of CT scans with hematomas detected that had hematoma detected by Infrascanner 2000 TM.
Specificity of InfraScanner 2000 TM for Detection of Any Size Hematoma at the Patient Level
Percentage of patients with no hematomas detected by CT who had no hematoma detected by Infrascanner 2000 TM.
Specificity of InfraScanner 2000 TM for Detection of Any Size Hematoma at the Scan Level
Percentage of CT scans with no hematomas detected that had no hematoma detected by Infrascanner 2000 TM.
False Positive Rate of InfraScanner 2000 TM for Detection of Any Size Hematoma at the Patient Level
Percentage of patients with no hematomas detected by CT that had hematoma detected by Infrascanner 2000 TM.
False Positive Rate of InfraScanner 2000 TM for Detection of Any Size Hematoma at the Scan Level
Percentage of scans with no hematomas detected by CT that had hematoma detected by Infrascanner 2000 TM.
False Negative Rate of InfraScanner 2000 TM for Detection of Any Size Hematoma at the Patient Level
Percentage of patients with hematomas detected by CT that had no hematoma detected by Infrascanner 2000 TM.
False Negative Rate of InfraScanner 2000 TM for Detection of Any Size Hematoma at the Scan Level
Percentage of scans with hematomas detected by CT that had no hematoma detected by Infrascanner 2000 TM.

Secondary Outcome Measures

Sensitivity in Identification of Hematomas Within Detection Limits, at the Patient Level
Percentage of subjects with hematomas within detection limits detected by CT who had hematoma detected by Infrascanner 2000 TM.
Specificity in Identification of Hematomas Within Detection Limits, at the Patient Level
Percentage of patients with no hematomas within detection limits detected by CT who had no hematoma detected by Infrascanner 2000 TM.
Sensitivity for Bleeds Within Detection Limits by Hematoma Type at the Patient Level
Percentage of subjects with hematomas within detection limits detected by CT that were detected by Infrascanner 2000 TM.
False Negative Value for Bleeds Within Detection Limits by Hematoma Type at the Patient Level
Percentage of subjects with hematomas within detection limits detected by CT where no hematoma was detected by Infrascanner 2000 TM.
Sensitivity for Bleeds Within Detection Limits by Hematoma Type at the Scan Level
Percentage of CT scans with hematomas within detection limits detected by CT that were detected by Infrascanner 2000 TM.
False Negative Value for Bleeds Within Detection Limits by Hematoma Type at the Scan Level
Percentage of CT scans with hematomas within detection limits detected by CT where no hematoma was detected by Infrascanner 2000 TM.

Full Information

First Posted
November 21, 2017
Last Updated
August 6, 2019
Sponsor
Duke University
search

1. Study Identification

Unique Protocol Identification Number
NCT03353246
Brief Title
Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas
Official Title
Assessment of Accuracy, Precision, and Feasibility of a Handheld Near-Infrared Light Device (InfraScanner 2000™) in Detecting Subdural and Epidural Hematomas in Patients Admitted to Duke University Hospital: A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2019
Overall Recruitment Status
Completed
Study Start Date
December 11, 2017 (Actual)
Primary Completion Date
May 4, 2018 (Actual)
Study Completion Date
May 4, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Duke University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this study is to determine the sensitivity, specificity, and positive and negative predictive values of the a portable near-infrared-based device (portable NIR-based device), the InfraScanner 2000™, to detect intracranial hematomas (epidural hematomas (EDH) and/or subdural hematomas (SDH)) in patients hospitalized at Duke University Hospital (DUH) who have sustained or who are suspected to have sustained head trauma and have consequently received a brain computed tomography (CT) scan(s).
Detailed Description
When applicable (conscious patient and/or family or legally authorized representative is present) the study will be introduced to the patient and relevant parties prior to the research team approaching the patient. While head trauma frequently results in impaired cognition and/or consciousness, and due to the urgency of these circumstances patients are often not accompanied by kin, whenever appropriate, the purpose of the research and the procedure will be explained in detail with all questions answered to the patient's and/or representative's satisfaction. Because patients who sustain head trauma injuries typically remain within the hospital for multiple days for monitoring and care, each participant may undergo multiple CT scans over the course of his or her hospitalization, affording the opportunity to one to numerous measurements from each patient during his or her hospital stay. Within 30 minutes following each CT scan, the study team will approach the patient to scan the patient's cranium with the InfraScanner 2000™ (Image A). The procedure will entail placing 8 plastic light guides upon the patient's scalp. The study team member will use the device to sequentially emit light through each of the 8 light guides so that the light is incident upon scalp (Image B). The device is engineered such that the light emitter and receiver are spaced ~4cm apart, allowing the light's intensity to be measured between adjacent light guides (Image C). This entire procedure, including greeting the patient, placing the light guides, gathering the data, and removing the light guides should take ~10 minutes each time. The number of CT scans the patient receives determines the number of potential data collections. The patient will be approached by the study team following each CT scan to be scanned with the InfraScanner 2000™ (20). The patient and/or representative may refuse a scan during any encounter, and as such, the scan will not be done. For each patient scanned with the InfraScanner 2000™ they will be de-identified with a subject number, with age, sex, gender, skin color, hair color, hair thickness, mechanism of injury, Glasgow Coma Scale score, and mean time elapsed between CT scan and near-infrared measurement. These data will be stored in de-identified form on Research Electronic Data Capture (REDCap) and/or Microsoft Excel 2016 on a secured DHTS server (S:\NSU_IRB\Pro00087011). The collection period for each research subject concludes 30-days following his or her initial measurement with the InfraScanner 2000™, patient discharge, or patient death.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Head Trauma, Craniocerebral Injuries, Crushing Skull Injury, Head Injuries, Head Injuries, Multiple, Head Injuries, Closed, Head Trauma,Closed, Head Trauma Injury, Head Trauma, Penetrating, Head Injury, Minor, Head Injury Major, Head Injury, Open, Injuries, Craniocerebral, Injuries, Head, Multiple Head Injury, Trauma, Head

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
500 (Actual)

8. Arms, Groups, and Interventions

Arm Title
InfraScanner 2000™
Arm Type
Experimental
Arm Description
All patients entered onto the trial will undergo at least one cranial scanning using the InfraScanner 2000™ within 30 minutes of CT. Patients will be scanned using the InfraScanner 2000™ within 30 minutes of each subsequent CT. Patients will know the results of the CT but not the InfraScanner 2000™. The standard for comparison will be determined as follows. A CT result that is positive for hematoma will be considered a true positive and a CT result that is negative for hematoma will be considered a true negative. In cases where the results of the CT are negative for hematoma and the results of the InfraScanner 2000™ are positive consideration of further follow-up will be given on a case-by-case basis.
Intervention Type
Device
Intervention Name(s)
InfraScanner 2000™
Intervention Description
The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
Primary Outcome Measure Information:
Title
Sensitivity of InfraScanner 2000 TM to Detect Any Size Hematoma at the Patient Level
Description
Percentage of subjects with hematomas detected by CT who had hematoma detected by Infrascanner 2000 TM.
Time Frame
Up to 30 days after first CT scan
Title
Sensitivity of InfraScanner 2000 TM to Detect Any Size Hematoma at the Scan Level
Description
Percentage of CT scans with hematomas detected that had hematoma detected by Infrascanner 2000 TM.
Time Frame
Up to 30 days after first CT scan
Title
Specificity of InfraScanner 2000 TM for Detection of Any Size Hematoma at the Patient Level
Description
Percentage of patients with no hematomas detected by CT who had no hematoma detected by Infrascanner 2000 TM.
Time Frame
Up to 30 days after first CT scan
Title
Specificity of InfraScanner 2000 TM for Detection of Any Size Hematoma at the Scan Level
Description
Percentage of CT scans with no hematomas detected that had no hematoma detected by Infrascanner 2000 TM.
Time Frame
Up to 30 days after first CT scan
Title
False Positive Rate of InfraScanner 2000 TM for Detection of Any Size Hematoma at the Patient Level
Description
Percentage of patients with no hematomas detected by CT that had hematoma detected by Infrascanner 2000 TM.
Time Frame
Up to 30 days after first CT scan
Title
False Positive Rate of InfraScanner 2000 TM for Detection of Any Size Hematoma at the Scan Level
Description
Percentage of scans with no hematomas detected by CT that had hematoma detected by Infrascanner 2000 TM.
Time Frame
Up to 30 days after first CT scan
Title
False Negative Rate of InfraScanner 2000 TM for Detection of Any Size Hematoma at the Patient Level
Description
Percentage of patients with hematomas detected by CT that had no hematoma detected by Infrascanner 2000 TM.
Time Frame
Up to 30 days after first CT scan
Title
False Negative Rate of InfraScanner 2000 TM for Detection of Any Size Hematoma at the Scan Level
Description
Percentage of scans with hematomas detected by CT that had no hematoma detected by Infrascanner 2000 TM.
Time Frame
Up to 30 days after first CT scan
Secondary Outcome Measure Information:
Title
Sensitivity in Identification of Hematomas Within Detection Limits, at the Patient Level
Description
Percentage of subjects with hematomas within detection limits detected by CT who had hematoma detected by Infrascanner 2000 TM.
Time Frame
Up to 30 days after first CT scan
Title
Specificity in Identification of Hematomas Within Detection Limits, at the Patient Level
Description
Percentage of patients with no hematomas within detection limits detected by CT who had no hematoma detected by Infrascanner 2000 TM.
Time Frame
Up to 30 days after first CT scan
Title
Sensitivity for Bleeds Within Detection Limits by Hematoma Type at the Patient Level
Description
Percentage of subjects with hematomas within detection limits detected by CT that were detected by Infrascanner 2000 TM.
Time Frame
Up to 30 days after first CT scan
Title
False Negative Value for Bleeds Within Detection Limits by Hematoma Type at the Patient Level
Description
Percentage of subjects with hematomas within detection limits detected by CT where no hematoma was detected by Infrascanner 2000 TM.
Time Frame
Up to 30 days after first CT scan
Title
Sensitivity for Bleeds Within Detection Limits by Hematoma Type at the Scan Level
Description
Percentage of CT scans with hematomas within detection limits detected by CT that were detected by Infrascanner 2000 TM.
Time Frame
Up to 30 days after first CT scan
Title
False Negative Value for Bleeds Within Detection Limits by Hematoma Type at the Scan Level
Description
Percentage of CT scans with hematomas within detection limits detected by CT where no hematoma was detected by Infrascanner 2000 TM.
Time Frame
Up to 30 days after first CT scan

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Any patient who presents to Duke University Hospital with suspected head trauma and receives a brain CT scan will be considered for this study. Exclusion Criteria: None
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Haglund, MD, PhD
Organizational Affiliation
Duke University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas

We'll reach out to this number within 24 hrs